Wild‐type (WT) sequence p53 peptides are attractive candidates for broadly applicable
cancer vaccines. The aim of this study was to evaluate the potential of a WT p53‐based …

Wild-type sequence (wt) p53 peptides are attractive candidates for broadly applicable
cancer vaccines. Six HLA-A2 or HLA-A24-restricted wt p53 peptides were evaluated for their …

Wild-type sequence (wt) p53 peptides are attractive candidates for broadly applicable
cancer vaccines. Evidence has been accumulating which indicates that CD4+ Th cells have …

Abstract p53 mutations are frequently found in human cancers and are often associated with
the overexpression of wild-type (WT) protein or peptide sequences, supporting the notion …

Immunization with wild-type sequence (wt) p53 epitopes represents a novel therapeutic
strategyfor cancer patients with tumors accumulating mutant p53. To evaluate usefulness of …

Tumor peptide-based vaccines are more effective when they include tumor-specific Th cell-
defined as well as CTL-defined peptides. Presently, two overlapping wild-type sequences …

High‐frequency mutation of the TP53 tumor suppressor gene is observed in multiple human
cancers, which promotes cancer progression. However, the mutated gene‐encoded protein …

Loss of p53 tumor-suppressor function is the most common abnormality in human cancer,
which can result in enhanced presentation to immune cells of wild-type (wt)-sequence …

Current evidence suggests that the optimal vaccines for cancer should incorporate tumor-
specific cytotoxic as well as helper epitopes. Wild-type sequence (wt) p53 peptides are …

Overexpression of p53 is found in∼ 50% of human cancers, making it an attractive target
antigen for immunotherapy of cancer. Research in this area has thus far primarily focused on …